Concepedia

Allison Moreau

AM

Statistics

Publications

8

Citations

346

H-Index

8

Active since

2009

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Pfizer (United States)

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Allison Moreau is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

2009–2023

8

Publications

8

Effects of Omeprazole on Plasma Levels of Raltegravir

Marian Iwamoto, Larissa Wenning, Bach‐Yen Nguyen et al. · Clinical Infectious Diseases · 2009 · 86 citations · Full text

, , +10

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Michael L. Maitland, Jasgit C. Sachdev, Manish Sharma et al. · Clinical Cancer Research · 2021 · 75 citations · Full text

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

Timothy A. Yap, Abdelaziz M. Elhaddad, Rachel N. Grisham et al. · Journal of Clinical Oncology · 2023 · 50 citations

, , +14

Pharmacokinetics and Pharmacodynamics of MK‐5046, a Bombesin Receptor Subtype‐3 (BRS‐3) Agonist, in Healthy Patients

Marc L. Reitman, Victor Dishy, Allison Moreau et al. · The Journal of Clinical Pharmacology · 2011 · 44 citations · Full text

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

William D. Hanley, Larissa Wenning, Allison Moreau et al. · Antimicrobial Agents and Chemotherapy · 2009 · 39 citations · Full text

, , +16

1–5 of 8